Tag
The Essence-TIMI 73b trial reveals that despite a 64% reduction in triglycerides and a 72% drop in remnant cholesterol via olezarsen, non-calcified coronary plaque volume remained unchanged over 12 months.
Two randomized trials found monthly olezarsen (50 mg and 80 mg) produced large, dose-dependent triglyceride reductions and a marked decrease in acute pancreatitis compared with placebo in patients with severe hypertriglyceridemia; higher do
Olezarsen, a GalNAc-conjugated antisense oligonucleotide targeting APOC3 mRNA, significantly reduces triglyceride levels in moderate hypertriglyceridemia, offering a promising therapeutic advance with favorable safety in cardiovascular risk
